Proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with diffuse systemic sclerosis: A marker of disease activity and severe disease manifestations with potential therapeutic implementations.
Joy ArtinYumn A AlsabbaghLaila RashedMohamed A HusseinPublished in: Archives of rheumatology (2022)
Serum PCSK9 is upregulated in d-SSc with higher levels in severe disease manifestations such as DU and ILD. It is correlated well with disease activity, more severe disease manifestations, and CIMT. The PCSK9 inhibitors may be a target of therapy in diseases with premature atherosclerosis such as d-SSc regardless of its anti-cholesterol effect, at least in more severe manifestations.
Keyphrases
- disease activity
- systemic sclerosis
- rheumatoid arthritis
- systemic lupus erythematosus
- low density lipoprotein
- interstitial lung disease
- rheumatoid arthritis patients
- ankylosing spondylitis
- early onset
- juvenile idiopathic arthritis
- drug induced
- type diabetes
- cardiovascular disease
- mesenchymal stem cells
- idiopathic pulmonary fibrosis
- smoking cessation